Fibrotic diseases appear to utilise this NR4A1-dependent mechanism to enable persistent TGF-β signaling and deregulated fibrosis and NR4A1 agonists inhibit laboratory-induced fibrosis of the skin, lung, liver, and kidney in mice [56, 57]. Here, TGFB1 is linked to fibrosis.